Piper Sandler Trims Taysha Gene Therapies (NASDAQ:TSHA) Target Price to $7.00

Taysha Gene Therapies (NASDAQ:TSHA) had its price target decreased by Piper Sandler from $9.00 to $7.00 in a report published on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other research firms have also weighed in on TSHA. Jefferies Financial Group reiterated a buy rating and issued a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Cantor Fitzgerald reiterated an overweight rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Chardan Capital reiterated a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, June 18th. BMO Capital Markets initiated coverage on Taysha Gene Therapies in a research note on Thursday, June 27th. They issued an outperform rating and a $5.00 target price on the stock. Finally, Needham & Company LLC restated a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday, June 17th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $6.60.

Taysha Gene Therapies Stock Down 0.5 %

Shares of TSHA opened at $2.15 on Monday. The company has a market cap of $402.09 million, a PE ratio of -4.39 and a beta of 0.42. The business has a fifty day moving average of $2.96 and a 200 day moving average of $2.43. Taysha Gene Therapies has a 52-week low of $0.61 and a 52-week high of $4.32. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same period last year, the company earned ($0.28) earnings per share. On average, sell-side analysts expect that Taysha Gene Therapies will post -0.43 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning bought 1,333,333 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the completion of the purchase, the insider now directly owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Howard Capital Management Inc. purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $25,000. Victory Capital Management Inc. purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $28,000. Dynamic Technology Lab Private Ltd purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $31,000. China Universal Asset Management Co. Ltd. purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $38,000. Finally, Cannon Global Investment Management LLC purchased a new position in Taysha Gene Therapies in the first quarter valued at about $69,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.